Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Saved in:
| Title: | Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. |
|---|---|
| Authors: | Tran G; Roche Products Pty Ltd, New South Wales, Australia. giao.tran@roche.com, Hack SP, Kerr A, Stokes L, Gibbs P, Price T, Todd C |
| Source: | Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2013 Sep; Vol. 9 (3), pp. 239-48. Date of Electronic Publication: 2012 Dec 21. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-7563 (Electronic) Linking ISSN: 17437555 NLM ISO Abbreviation: Asia Pac J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
